Abstracts tagged "autoantibodies"

Abstract Number: 915 • 2016 ACR/ARHP Annual Meeting
Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomoyuki Muto², Yuko Shirota¹, Yoko Fujita³, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Autoantibodies which recognize integral membrane proteins are generally accepted as pathogenic. However, it had been technically difficult to identify plasma membrane proteins as autoantigens…
Abstract Number: 2114 • 2016 ACR/ARHP Annual Meeting
Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity
Jacqueline Dekkers¹, Marije K. Verheul², Jeroen Stoop³, Bisheng Liu⁴, Peter A. van Veelen⁵, Martin Hegen⁶, Stephen Rapecki⁷, Tom WJ Huizinga², Leendert A. Trouw⁴ and René Toes⁴, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, ⁶Inflammation, Wyeth Pharmaceuticals, Cambridge, MA, ⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Autoantibodies are an important hallmark of Rheumatoid Arthritis (RA). Approximately 50% of RA patients harbor anti-carbamylated protein (CarP) antibodies. These autoantibodies target proteins that…
Abstract Number: 3020 • 2016 ACR/ARHP Annual Meeting
Citrullination of Inhibitor of DNA Binding-1 at Specific Locations Leads to Autoantigenicity in Rheumatoid Arthritis
Ray A. Ohara¹, Henriette A. Remmer², Phillip L. Campbell³, David A. Fox³ and Jeffrey H. Ruth³, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding-1 (Id1) is a nuclear transcription factor that regulates cell growth and differentiation via selective binding and sequestering of other transcription…
Abstract Number: 166 • 2016 ACR/ARHP Annual Meeting
Prevalence of Radiographic Thymic Alteration and Its Clinical Association in Systemic Autoimmune Diseases
Okinori Murata¹, Katsuya Suzuki¹, Hiroaki Sugiura², Yasushi Kondo¹, Hidekata Yasuoka¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi¹, ¹Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ²Keio University School of Medcine, Division of Diagnostic Radiology, Department of Radiology, Tokyo, Japan
Background/Purpose: Consecutive and unbiased 500 patients who had visited at our service and had been evaluated by chest CT scan between January 2013 and December…
Abstract Number: 926 • 2016 ACR/ARHP Annual Meeting
Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis
Linda Johansson¹, Lisbeth Ärlestig¹, Heidi Kokkonen² and Solbritt Rantapaa-Dahlqvist³, ¹Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ³Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden
Background/Purpose: Receptor activator of nuclear factor κB ligand (RANKL) an important regulator of bone metabolism has a key role in local bone destruction and osteoporosis…
Abstract Number: 2118 • 2016 ACR/ARHP Annual Meeting
Rituximab Treated Non Responder Rheumatoid Arthritis Patients Are Generating a New Autoantibody Repertoire
Zoltan Konthur¹, Melvin Michael Wiemkes², Thomas Häupl³, Gerd R. Burmester⁴ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann Rheum Dis.…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting
Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami¹, Yoshitaka Imura¹, Satoshi Serada², Minoru Fujimoto³, Hajime Yoshifuji¹, Koichiro Ohmura⁴, Tetsuji Naka⁵ and Tsuneyo Mimori⁴, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ³Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ⁴Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
Background/Purpose: Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…
Abstract Number: 989 • 2016 ACR/ARHP Annual Meeting
A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study
Jeffrey A. Sparks¹, Maura D. Iversen², Zhi Yu³, Nellie A. Triedman³, Maria G. Prado³, Rachel Miller Kroouze⁴, Sarah S. Kalia⁵, Elinor A. Mody³, Simon M. Helfgott³, Derrick J. Todd³, Paul F. Dellaripa³, Bonnie L. Bermas³, Kevin D. Deane⁶, Karen H. Costenbader³, Bing Lu³, Robert C. Green⁵ and Elizabeth W. Karlson³, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose : Disclosure of genetic risk information alone has had limited impact on changing health behaviors in research trials. Prior studies have not evaluated whether…
Abstract Number: 2307 • 2016 ACR/ARHP Annual Meeting
Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease
Naoshi Nishina¹, Shinji Sato², Yasushi Kawaguchi³, Atsushi Kawakami⁴, Maasa Tamura⁵, Kei Ikeda⁶, Takahiro Nunokawa⁷, Yoshinori Tanino⁸, Katsuaki Asakawa⁹, Yuko Kaneko¹⁰, Takahisa Gono¹¹, Kenichi Masui¹², Masataka Kuwana¹ and JAMI investigators, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁷Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁸Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹¹Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan, ¹²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan
Background/Purpose: Environmental triggers such as infection are considered to be involved in pathogenesis of polymyositis (PM) and dermatomyositis (DM). This study was aimed to investigate…
Abstract Number: 3239 • 2016 ACR/ARHP Annual Meeting
Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Malin Hedlund¹, Gudny-Ella Thorlacius¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Joanna Tingstrom¹, Alexander Espinosa¹, Lars Rönnblom², Maija-Leena Eloranta², Sven-Erik Sonesson¹ and Marie Wahren-Herlenius³, ¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Stockholm, Sweden, ²Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ³Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Ro/SSA autoantibodies and an IFN signature are commonly present in women with Sjögren’s syndrome and SLE. During pregnancy, the autoantibodies are transported across the…
Abstract Number: 281 • 2016 ACR/ARHP Annual Meeting
Characterization of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies
Takayuki Kishi¹, Andrew Mammen^2,3, Katherine Pak², Lilliana Barillas-Arias⁴, Michael Henrickson⁵, Paul L. McCarthy⁶, Bracha Shaham⁷, Pamela F. Weiss⁸, Iren Horkayne-Szakaly⁹, Frederick W. Miller¹⁰, Lisa G. Rider¹⁰ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ⁴Bernard & Millie Duker Children's Hospital, Albany Medical Center, Albany, NY, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics, Yale University School of Medicine, New Haven, CT, ⁷Pediatric Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁸Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁹Joint Pathology Center, Defense Health Agency, Silver Spring, MD, ¹⁰Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies (Abs) to 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (HMGCR) identified in adult myositis patients with immune-mediated necrotizing myopathies (IMNM) have been associated with severe weakness,…
Abstract Number: 1079 • 2016 ACR/ARHP Annual Meeting
Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease
Peter Schulz-Knappe¹, Petra Budde¹, Hans-Dieter Zucht¹, Heike Göhler¹, Klaus Marquart¹, Prof. Dr. Matthias Schneider² and Torsten Witte³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common autoimmune disease with exocrine gland dysfunction and multi-organ involvement. With the growing interest in conducting clinical trials…
Abstract Number: 2312 • 2016 ACR/ARHP Annual Meeting
Anti-TIF1-Gamma Antibodies Are Not Associated with Other Paraneoplastic Rheumatic Syndromes Than Dermatomyositis
Paulius Venalis¹, Sandra Selickaja^2,3, Karin Lundberg⁴, Rita Rugiene^5,6 and Ingrid E. Lundberg⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Vilnius University, Center of Rheumatology;, Vilnius, Lithuania, ³State Research Institute for Innovative Medicine, Vilnius, Lithuania, ⁴Rheumatology Unit, Department, Karolinska Institute, Stockholm, Sweden, ⁵Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ⁶State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, ⁷Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: An association between cancer and dermatomyositis (DM), referred to as cancer-associated myositis, is well recognized and clinically important. The overall cancer risk is up…
Abstract Number: 282 • 2016 ACR/ARHP Annual Meeting
From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’
Yves Allenbach¹, Louiza Arouche-Delaperche², Corinna Preusse³, Gillian Butler Browne², Nicolas Champtiaux⁴, Kuberaka Mariampillai⁵, Aude Rigolet⁶, Peter Hufnagl⁷, Norman Zerbe⁸, Thierry Maisonobe⁹, Damien Amelin², Sarah Leonard-louis¹⁰, Charles Duyckaerts¹¹, Bruno Eymard¹², Hans-Hilmar Goebel³, Laurent Drouot¹³, Olivier Boyer¹⁴, Olivier Benveniste^2,5 and Werner Stenzel³, ¹Pitié-Salpêtrière University Hospital, AP-HP, Department of Internal Medicine and Clinical Immunology, Paris, France, Paris, France, ²Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ³Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ⁴Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ⁶Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁷Pathology departmen, Charite Hospital, Berlin, Germany, ⁸Department of Pathology, Charite Hospital, Berlin, Germany, ⁹Pitié-Salpêtrière University Hospital, AP-HP, Department of Neuropathology, Paris, France, Paris, France, ¹⁰Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Neuropathology, Paris, France, Paris, France, ¹¹Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ¹²Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ¹³Immunology, INSERM U905, University of Rouen, Rouen, France, ¹⁴Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Immune mediated necrotizing myopathy (IMNM) has been recently added as a new entity among dermatomyositis, polymyositis and sporadic inclusion body myositis. IMNM is defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].